TRISCEND II Pivotal Trial

What is the Purpose of this Study?

This study focuses on adults who have tricuspid regurgitation (TR), a condition in which the heart's tricuspid valve does not close tightly, causing blood to flow backwards in the wrong direction. The purpose of the study is to evaluate the safety and effectiveness of an investigational device called the EVOQUE system with Optimal Medical Therapy (OMT) compared to OMT alone in the treatment of patients with severe or greater tricuspid regurgitation. The EVOQUE Valve is an artificial valve made from bovine pericardial (cow heart) tissue, nitinol (metal) frame, and a fabric skirt. The valve is designed to replace the tricuspid heart valve without open-heart surgery and is implanted using a delivery catheter.

Eligibility

* Age ≥ 18 years old
* Despite medical therapy (OMT) per the local Heart Team, patient has signs of TR, symptoms from TR, or prior heart failure hospitalization from TR. Patient must be on OMT per the local heart team at the time of TR assessment for trial eligibility (TTE). OMT includes stable oral diuretic medications, unless patient has a documented history of intolerance.
* Functional and/or degenerative TR graded as at least severe on a transthoracic echocardiogram (assessed by the echo core lab using a 5-grade classification)
* The Local Heart Team determines that the patient is appropriate for transcatheter tricuspid valve replacement

Inclusion Criteria:

* Age ≥ 18 years old
* Despite medical therapy (OMT) per the local Heart Team, patient has signs of TR, symptoms from TR, or prior heart failure hospitalization from TR. Patient must be on OMT per the local heart team at the time of TR assessment for trial eligibility (TTE). OMT includes stable oral diuretic medications, unless patient has a documented history of intolerance.
* Functional and/or degenerative TR graded as at least severe on a transthoracic echocardiogram (assessed by the echo core lab using a 5-grade classification)
* The Local Heart Team determines that the patient is appropriate for transcatheter tricuspid valve replacement
* Patient is willing and able to comply with all study evaluations and provides written informed consent.

Exclusion Criteria:

* Anatomy precluding proper device delivery, deployment and/or function
* LVEF \< 25%
* Evidence of severe right ventricular dysfunction
* Any of the following pulmonary pressure parameters:
1. PASP \>60 mmHg by echo Doppler (unless RHC demonstrates PASP ≤70 mmHg)
2. PASP \>70 mmHg by RHC
3. PVR \>5 Wood units by RHC (unless PVR ≤5 Wood units and systolic BP \>85 mmHg after vasodilator challenge)
* Previous tricuspid surgery or intervention
* Presence of trans-tricuspid pacemaker or defibrillator lead with any of the following:
1. Implanted in the RV within the last90 days
2. Patient is pacemaker dependent5 on trans-tricuspid lead without alternative pacing option
3. Has delivered appropriate ICD therapy
* Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation.
* Active endocarditis within the last 90 days or infection requiring antibiotic therapy (oral or intravenous) within the last 14 days
* Hemodynamically significant pericardial effusion
* Significant intra-cardiac mass, thrombus, or vegetation.
* Clinically significant, untreated coronary artery disease requiring revascularization, evidence of acute coronary syndrome, recent myocardial infarction within the last 30 days.
* Any of the following cardiovascular procedures:
1. Percutaneous coronary, intracardiac, or endovascular intervention within the last 30 days
2. Carotid surgery within the last 30 days
3. Direct current cardioversion within the last 30 days
4. Leadless RV pacemaker implant within the last 30 days
5. Cardiac surgery within the last 90 days
* Known history of untreated severe symptomatic carotid stenosis (\>50% by ultrasound) or asymptomatic carotid stenosis (\>70% by ultrasound)
* Need for emergent or urgent surgery for any reason, any planned cardiac surgery within the next 12 months (365days), or any planned percutaneous cardiac procedure within the next 90 days
* Hypotension (systolic pressure \<90 mmHg) or requirement for inotropic support or hemodynamic support within the last 30 days
* Patient with refractory heart failure requiring or which required advanced intervention (i.e. left ventricular assist device, transplantation) (ACC/AHA/ESC/EACTS Stage D heart failure)
* Deep vein thrombosis (DVT) or pulmonary embolism (PE) in the last 6 months (180 days)
* Stroke within the last 90 days
* Modified Rankin Scale ≥ 4 disability
* Severe renal insufficiency with estimated glomerular filtration rate (eGFR) ≤ 25 mL/min/1.73m2 or requiring chronic renal replacement therapy.
* Patients with hepatic insufficiency or cirrhosis with Child-Pugh score class C
* Patient is oxygen-dependent or requires continuous home oxygen
* Chronic anemia with transfusion dependency or Hgb \< 9 g/dL not corrected by transfusion
* Unable to walk at least 100 meters in a 6-minute walk test
* Thrombocytopenia (Platelet count \< 75,000/mm3) or thrombocytosis (Platelet count \> 750,000/mm3)
* Known bleeding or clotting disorders or patient refuses blood transfusion
* Active gastrointestinal (GI) bleeding within the last 90 days
* Pregnant, breastfeeding, or planning pregnancy within the next 12 months (365 days).
* Patients in whom (any of the following):
1. TEE is contraindicated or cannot be completed
2. tricuspid valve anatomy is not evaluable by TTE or TEE
* In the opinion of the investigator, access to and through the femoral vein/IVC with a guide sheath and delivery catheter is deemed not feasible (e.g. occluded femoral veins, occluded or thrombosed IVC filter)
* Untreatable hypersensitivity or contraindication to any of the following: all antiplatelets, all anticoagulants, nitinol alloys (nickel and titanium), bovine tissue, glutaraldehyde, or contrast media
* Currently participating in another investigational biologic, drug or device study
* Co-morbid condition(s) that, in the opinion of the Investigator, limit life expectancy to \< 12 months (365 days).
* Presence of infiltrative cardiomyopathy or valvulopathy (including carcinoid, amyloidosis, sarcoidosis, hemochromatosis) or significant uncorrected congenital heart disease (including but not limited to hemodynamically significant atrial septal defect, RV dysplasia, and arrhythmogenic RV)
* Any condition, in the opinion of the investigator, making it unlikely the patient will be able to complete all protocol procedures and follow-ups
* Other medical, social, or psychological conditions that preclude appropriate consent and follow-up, including patients under guardianship
* Any patient considered to be vulnerable

Show less

Where can I participate?

Beverly

More about this Clinical Trial

What is the full name of this clinical trial?

Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device

Study Details

Disease Type/Condition

Valvular Heart Disease

Principal Investigator

Makkar, Rajendra

Age Group

Adult

Phase

III

IRB Number

STUDY00000967

ClinicalTrials.gov ID

NCT04482062

Key Eligibility

ClinicalTrials.gov

How do I learn more about this study?

clinicaltrials@cshs.org